Trial Profile
Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura, Thymus or Mediastinum
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Alvocidib (Primary) ; Romidepsin (Primary)
- Indications Lung cancer; Malignant thymoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Sarcoma; Small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- 01 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 01 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 22 Aug 2012 Actual end date (Aug 2012) added as reported by ClinicalTrials.gov.